Menovo(SH:603538) Ge Long Hui A P P·2025-10-20 09:03Core Viewpoint - Meinuo Pharma has received approval from the National Medical Products Administration for the production and sale of Irbesartan Hydrochlorothiazide tablets, enhancing its market competitiveness and expanding its cardiovascular product pipeline [1] Group 1 - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Irbesartan Hydrochlorothiazide tablets [1] - The drug is indicated for the treatment of primary hypertension, which addresses a significant health issue [1] - The approval marks a significant milestone for the company, allowing it to produce and sell the drug in the domestic market [1] Group 2 - The introduction of this product is expected to positively impact the company's operational development [1] - The approval enhances the company's product offerings in the cardiovascular segment, which is crucial for growth in this therapeutic area [1]